XENE: Xenon Pharmaceuticals Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
2 open-market buys totaling $1.68M and 0 sales totaling - in the last 180 days.
Insider buys
| Score | Ticker | Company | Insider | Role | Trade date | Value | Holding + | Cluster |
|---|---|---|---|---|---|---|---|---|
| 64 | XENE | Xenon Pharmaceuticals Inc. | Kelly Thomas Patrick | CFO | 2026-09-30 | $560K | new | 2 insiders |
| 73 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | CEO | 2026-09-30 | $1.12M | 151% | 2 insiders |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.